High Throughput Isolation and Data Independent Acquisition Mass Spectrometry (DIA-MS) of Urinary Extracellular Vesicles to Improve Prostate Cancer Diagnosis.
Hao ZhangGui-Yuan ZhangWei-Chao SuYa-Ting ChenYu-Feng LiuDong WeiYan-Xi ZhangQiu-Yi TangYu-Xiang LiuShi-Zhi WangWen-Chao LiAnke WesseliusMaurice P ZeegersZi-Yu ZhangYan-Hong GuWeiguo Andy TaoEvan Yi-Wen YuPublished in: Molecules (Basel, Switzerland) (2022)
Proteomic profiling of extracellular vesicles (EVs) represents a promising approach for early detection and therapeutic monitoring of diseases such as cancer. The focus of this study was to apply robust EV isolation and subsequent data-independent acquisition mass spectrometry (DIA-MS) for urinary EV proteomics of prostate cancer and prostate inflammation patients. Urinary EVs were isolated by functionalized magnetic beads through chemical affinity on an automatic station, and EV proteins were analyzed by integrating three library-base analyses (Direct-DIA, GPF-DIA, and Fractionated DDA-base DIA) to improve the coverage and quantitation. We assessed the levels of urinary EV-associated proteins based on 40 samples consisting of 20 cases and 20 controls, where 18 EV proteins were identified to be differentiated in prostate cancer outcome, of which three (i.e., SERPINA3, LRG1, and SCGB3A1) were shown to be consistently upregulated. We also observed 6 out of the 18 (33%) EV proteins that had been developed as drug targets, while some of them showed protein-protein interactions. Moreover, the potential mechanistic pathways of 18 significantly different EV proteins were enriched in metabolic, immune, and inflammatory activities. These results showed consistency in an independent cohort with 20 participants. Using a random forest algorithm for classification assessment, including the identified EV proteins, we found that SERPINA3, LRG1, or SCGB3A1 add predictable value in addition to age, prostate size, body mass index (BMI), and prostate-specific antigen (PSA). In summary, the current study demonstrates a translational workflow to identify EV proteins as molecular markers to improve the clinical diagnosis of prostate cancer.
Keyphrases
- prostate cancer
- mass spectrometry
- radical prostatectomy
- body mass index
- liquid chromatography
- machine learning
- high throughput
- deep learning
- high performance liquid chromatography
- oxidative stress
- single cell
- gas chromatography
- squamous cell carcinoma
- ejection fraction
- high resolution
- healthcare
- electronic health record
- newly diagnosed
- chronic kidney disease
- prognostic factors
- patient reported outcomes
- benign prostatic hyperplasia
- artificial intelligence
- health insurance
- tandem mass spectrometry